Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jul;6(7):1214-1224.
doi: 10.1002/acn3.50800. Epub 2019 Jun 12.

Identification of serum microRNAs as potential biomarkers in Pompe disease

Ana Carrasco-Rozas  1 , Esther Fernández-Simón  1 , Maria Cinta Lleixà  1 , Izaskun Belmonte  2 , Irene Pedrosa-Hernandez  2 , Elena Montiel-Morillo  2 , Claudia Nuñez-Peralta  3 , Jaume Llauger Rossello  3 , Sonia Segovia  1   4 , Noemí De Luna  1   4 , Xavier Suarez-Calvet  1   4 , Isabel Illa  1   4 ; Pompe Spanish Study group; Jordi Díaz-Manera  1   4 , Eduard Gallardo  1   4
Collaborators, Affiliations
Clinical Trial

Identification of serum microRNAs as potential biomarkers in Pompe disease

Ana Carrasco-Rozas et al. Ann Clin Transl Neurol. 2019 Jul.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Ann Clin Transl Neurol. 2022 Jun;9(6):897. doi: 10.1002/acn3.51600. Epub 2022 Jun 6. Ann Clin Transl Neurol. 2022. PMID: 35665494 Free PMC article. No abstract available.

Abstract

Objective: To analyze the microRNA profile in serum of patients with Adult Onset Pompe disease (AOPD).

Methods: We analyzed the expression of 185 microRNAs in serum of 15 AOPD patients and five controls using microRNA PCR Panels. The expression levels of microRNAs that were deregulated were further studied in 35 AOPD patients and 10 controls using Real-Time PCR. Additionally, the skeletal muscle expression of microRNAs which showed significant increase levels in serum samples was also studied. Correlations between microRNA serum levels and muscle function test, spirometry, and quantitative muscle MRI were performed (these data correspond to the study NCT01914536 at ClinicalTrials.gov).

Results: We identified 14 microRNAs that showed different expression levels in serum samples of AOPD patients compared to controls. We validated these results in a larger cohort of patients and we found increased levels of three microRNAs, the so called dystromirs: miR-1-3p, miR-133a-3p, and miR-206. These microRNAs are involved in muscle regeneration and the expression of these was increased in patients' muscle biopsies. Significant correlations between microRNA levels and muscle function test were found.

Interpretation: Serum expression levels of dystromirs may represent additional biomarkers for the follow-up of AOPD patients.

PubMed Disclaimer

Conflict of interest statement

This study (GZ‐2015‐11342) has been performed with funding from SANOFI/Genzyme.

Figures

Figure 1
Figure 1
Normalized relative expression levels of validated serum miRNAs in Pompe patients. Data are presented as mean ± SD. Mann–Whitney U test *P < 0.05, **P < 0.01 and ***P < 0.001.
Figure 2
Figure 2
Normalized relative expression levels of serum miRNAs in Pompe patients. Data are presented as mean ± SD. Mann–Whitney U test.
Figure 3
Figure 3
Dystromir expression changes in Pompe patients in response to the treatment. Data are presented as fold change values in post‐ERT patients regarding their pre‐ERT samples.
Figure 4
Figure 4
Normalized relative expression levels of muscle miRNAs in Pompe patients. Data are presented as mean ± SD. Mann–Whitney U test *P < 0.05.
See this image and copyright information in PMC

References

    1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372:1342–1353. - PubMed
    1. Nascimbeni AC, Fanin M, Masiero E, et al. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ 2012;19:1698–1708. - PMC - PubMed
    1. Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin 2014;32:751–776. - PMC - PubMed
    1. Manganelli F, Ruggiero L. Clinical features of Pompe disease. Acta Myol 2013;32:82–84. - PMC - PubMed
    1. Desnuelle C, Salviati L. Challenges in diagnosis and treatment of late‐onset Pompe disease. Curr Opin Neurol 2011;24:443–448. - PubMed

Publication types

Associated data